Mike Doustdar
Coverage of Mike Doustdar in the Nexus archive.
- STAT+: Pharmalittle: We’re reading about Medicare and obesity drugs, Germany’s pricing plans, and more
Medicare will cover weight loss drugs for adults 65 and older starting next month via a temporary government program. Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight loss pill soon amid competition from generic drugmakers.
- Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
Novo Nordisk CEO Mike Doustdar highlights the potential of the company's obesity drugs, such as Ozempic and Wegovy, to impact longevity and other healthcare areas beyond weight loss. The drugs' active ingredient, semaglutide, shows possible benefits for organ protection and slowing aging-related processes, even before significant weight loss. Investors are urging the company to diversify as competitors like Eli Lilly expand into broader markets.
- Novo Nordisk CEO says the drugmaker is more active than ever in seeking out deals
Novo Nordisk is actively seeking deals, according to CEO Mike Doustdar. The company, known for Ozempic and Wegovy, is looking for more deals than ever before. This indicates a strategic expansion or partnership effort by the drugmaker.